FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3137141915> ?p ?o ?g. }

• W3137141915 endingPage "176" @default.
• W3137141915 startingPage "167" @default.
• W3137141915 abstract "Recent studies show that intracellular accumulation of cholesterol leads to acquired resistance to gefitinib in non-small cell lung cancer (NSCLC) cells. In this study we investigated how to regulate the cholesterol levels in gefitinib-resistant NSCLC cells. We showed that intracellular cholesterol levels in gefitinib-resistant cell lines (PC-9/GR, H1975, H1650, and A549) were significantly higher than that in gefitinib-sensitive cell line (PC-9). Treatment with gefitinib (5 μM) significantly increased intracellular cholesterol levels in PC-9/GR, H1975, and H1650 cells. Gefitinib treatment downregulated the expression of PPARα, LXRα, and ABCA1, leading to dysregulation of cholesterol efflux pathway. We found that a lipid-lowering drug fenofibrate (20, 40 μM) dose-dependently increased the expression of PPARα, LXRα, and ABCA1, decreased the intracellular cholesterol levels, and enhanced the antiproliferative effects of gefitinib in PC-9/GR, H1975, and H1650 cells. We revealed that fenofibrate increased the gefitinib-induced apoptosis via regulating the key proteins involved in the intrinsic apoptosis pathway. In PC-9/GR, H1975 and H1650 cells, fenofibrate dose-dependently increased the expression of AMPK, FoxO1, and decreased the expression of AKT, which were remarkably weakened by knockdown of PPARα. In PC-9/GR cell xenograft mice, combined administration of gefitinib (25 mg · kg-1 · d-1) and fenofibrate (100 mg · kg-1 · d-1) caused remarkable inhibition on tumor growth as compared to treatment with either drug alone. All the results suggest that fenofibrate relieves acquired resistance to gefitinib in NSCLC by promoting apoptosis via regulating PPARα/AMPK/AKT/FoxO1 pathway. We propose that combination of gefitinib and fenofibrate is a potential strategy for overcoming the gefitinib resistance in NSCLC." @default.
• W3137141915 created "2021-03-29" @default.
• W3137141915 creator A5012675662 @default.
• W3137141915 creator A5012903491 @default.
• W3137141915 creator A5023385821 @default.
• W3137141915 creator A5028433300 @default.
• W3137141915 creator A5033388228 @default.
• W3137141915 creator A5047106388 @default.
• W3137141915 creator A5049886847 @default.
• W3137141915 creator A5055931007 @default.
• W3137141915 creator A5060148518 @default.
• W3137141915 creator A5070080698 @default.
• W3137141915 creator A5075877965 @default.
• W3137141915 date "2021-03-26" @default.
• W3137141915 modified "2023-10-13" @default.
• W3137141915 title "PPARα agonist fenofibrate relieves acquired resistance to gefitinib in non-small cell lung cancer by promoting apoptosis via PPARα/AMPK/AKT/FoxO1 pathway" @default.
• W3137141915 cites W1659692600 @default.
• W3137141915 cites W1967588809 @default.
• W3137141915 cites W1979332174 @default.
• W3137141915 cites W2013849862 @default.
• W3137141915 cites W2022048961 @default.
• W3137141915 cites W2054851194 @default.
• W3137141915 cites W2067553189 @default.
• W3137141915 cites W2071322608 @default.
• W3137141915 cites W2072091107 @default.
• W3137141915 cites W2072362233 @default.
• W3137141915 cites W2082011949 @default.
• W3137141915 cites W2082843745 @default.
• W3137141915 cites W2084411547 @default.
• W3137141915 cites W2091727117 @default.
• W3137141915 cites W2126709309 @default.
• W3137141915 cites W2144437066 @default.
• W3137141915 cites W2318531023 @default.
• W3137141915 cites W2518669575 @default.
• W3137141915 cites W2530768869 @default.
• W3137141915 cites W2771188640 @default.
• W3137141915 cites W2782608603 @default.
• W3137141915 cites W2784371446 @default.
• W3137141915 cites W2788719551 @default.
• W3137141915 cites W2795708883 @default.
• W3137141915 cites W2802435476 @default.
• W3137141915 cites W2889646458 @default.
• W3137141915 cites W2895002883 @default.
• W3137141915 cites W2903819389 @default.
• W3137141915 cites W2908848549 @default.
• W3137141915 cites W2913273819 @default.
• W3137141915 cites W2914816455 @default.
• W3137141915 cites W2917696006 @default.
• W3137141915 cites W2944556507 @default.
• W3137141915 cites W2972509428 @default.
• W3137141915 cites W2982686049 @default.
• W3137141915 cites W3012686598 @default.
• W3137141915 doi "https://doi.org/10.1038/s41401-021-00638-z" @default.
• W3137141915 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33772142" @default.
• W3137141915 hasPublicationYear "2021" @default.
• W3137141915 type Work @default.
• W3137141915 sameAs 3137141915 @default.
• W3137141915 citedByCount "9" @default.
• W3137141915 countsByYear W31371419152021 @default.
• W3137141915 countsByYear W31371419152022 @default.
• W3137141915 countsByYear W31371419152023 @default.
• W3137141915 crossrefType "journal-article" @default.
• W3137141915 hasAuthorship W3137141915A5012675662 @default.
• W3137141915 hasAuthorship W3137141915A5012903491 @default.
• W3137141915 hasAuthorship W3137141915A5023385821 @default.
• W3137141915 hasAuthorship W3137141915A5028433300 @default.
• W3137141915 hasAuthorship W3137141915A5033388228 @default.
• W3137141915 hasAuthorship W3137141915A5047106388 @default.
• W3137141915 hasAuthorship W3137141915A5049886847 @default.
• W3137141915 hasAuthorship W3137141915A5055931007 @default.
• W3137141915 hasAuthorship W3137141915A5060148518 @default.
• W3137141915 hasAuthorship W3137141915A5070080698 @default.
• W3137141915 hasAuthorship W3137141915A5075877965 @default.
• W3137141915 hasBestOaLocation W31371419151 @default.
• W3137141915 hasConcept C104317684 @default.
• W3137141915 hasConcept C121608353 @default.
• W3137141915 hasConcept C126322002 @default.
• W3137141915 hasConcept C134018914 @default.
• W3137141915 hasConcept C149011108 @default.
• W3137141915 hasConcept C184235292 @default.
• W3137141915 hasConcept C185592680 @default.
• W3137141915 hasConcept C190283241 @default.
• W3137141915 hasConcept C2777704780 @default.
• W3137141915 hasConcept C2778110834 @default.
• W3137141915 hasConcept C2779438470 @default.
• W3137141915 hasConcept C2780124434 @default.
• W3137141915 hasConcept C2780499067 @default.
• W3137141915 hasConcept C2780580887 @default.
• W3137141915 hasConcept C502942594 @default.
• W3137141915 hasConcept C55493867 @default.
• W3137141915 hasConcept C62112901 @default.
• W3137141915 hasConcept C71924100 @default.
• W3137141915 hasConcept C75217442 @default.
• W3137141915 hasConcept C86554907 @default.
• W3137141915 hasConcept C97029542 @default.
• W3137141915 hasConcept C98274493 @default.
• W3137141915 hasConceptScore W3137141915C104317684 @default.
• W3137141915 hasConceptScore W3137141915C121608353 @default.

• next